title: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
abstract: A randomized controlled trial has begun in Japan to compare orally administered S-1 with intravenous gemcitabine (GEM) as adjuvant chemotherapy for patients with curatively resected pancreatic cancer. Patients are enrolled within 10 weeks after pancreatectomy to be treated for six months after assignment to either S-1 (80 mg/m(2)/day for four weeks, repeated similarly every six weeks for a total of four courses) or GEM (1000 mg/m(2) on days 1, 8 and 15, repeated similarly every four weeks for a total of six courses). The primary endpoint is overall survival; secondary endpoints include relapse-free survival, incidence of adverse events and health-related quality of life. Each treatment arm includes 180 patients, providing an expected hazard ratio of 0.87 and an upper margin of 1.25 (two-sided alpha-error, 0.05; power, 0.8). Follow-up abdominal computed tomography is repeated every three months during the first two years, then every six months for three years.
authors.affiliation: Shizuoka Cancer Center Hospital, Division of Hepato-Biliary-Pancreatic Surgery, 1007 Shimo-Nagakubo, Sunto-Nagaizumi, Shizuoka, 411-8777 Japan. a.maeda@scchr.jp
authors.forename: Atsuyuki
authors.initials: A
authors.lastname: Maeda
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
authors.forename: Akira
authors.initials: A
authors.lastname: Fukutomi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kondo
authors.forename: Taira
authors.initials: T
authors.lastname: Kinoshita
authors.forename: Masato
authors.initials: M
authors.lastname: Nagino
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Uesaka
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D007275:Injections, Intravenous; D007564:Japan / Q000453:epidemiology; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011446:Prospective Studies; D011788:Quality of Life; D015996:Survival Rate; D005641:Tegafur / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine